Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

181. Prognosis of MTA Apexification Versus Calcium Hydroxide Apexification

Prognosis of MTA Apexification Versus Calcium Hydroxide Apexification UTCAT830, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Prognosis Of MTA Apexification Versus Calcium Hydroxide Apexification Clinical Question Does MTA apexification render better long-term prognosis than calcium hydroxide apexification for treatment of dens in dente in permanent dentition from children or adolescents? Clinical Bottom Line When (...) performed correctly, apexification with MTA and calcium hydroxide on permanent dentition with dens in dente and open apices both have similarly good long-term prognosis. However, given that MTA is more biocompatible and that it can be performed in one visit, MTA apexification is the treatment of choice. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Jaramillo/2006 Children to adolescent with dens in dente

2011 UTHSCSA Dental School CAT Library

182. Effect of a high-calcium energy-reduced diet on abdominal obesity and cardiometabolic risk factors in obese Brazilian subjects (PubMed)

Effect of a high-calcium energy-reduced diet on abdominal obesity and cardiometabolic risk factors in obese Brazilian subjects 20642707 2010 07 20 2011 11 10 2010 07 20 1742-1241 64 8 2010 Jul International journal of clinical practice Int. J. Clin. Pract. Effect of a high-calcium energy-reduced diet on abdominal obesity and cardiometabolic risk factors in obese Brazilian subjects. 1076-83 10.1111/j.1742-1241.2009.02312.x Clinical trials designed to examine the effects of calcium (...) supplementation on abdominal obesity have had ambiguous results. This study aimed to evaluate, during energy restriction, the effects of a high-calcium diet (HCD) on measures of abdominal obesity and cardiometabolic risk factors in Brazilian obese subjects of multiethnic origin. We conducted a randomised clinical trial. Fifty obese subjects of both sexes, aged 22-55 years, with stable body weight and a low calcium intake were randomised into the following outpatient dietary regimens: (i) a low-calcium diet

2010 EvidenceUpdates

183. Nonoptimal Lipids Commonly Present in Young Adults and Coronary Calcium Later in Life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study. (PubMed)

Nonoptimal Lipids Commonly Present in Young Adults and Coronary Calcium Later in Life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study. BACKGROUND: Dyslipidemia causes coronary heart disease in middle-aged and elderly adults, but the consequences of lipid exposure during young adulthood are unclear. OBJECTIVE: To assess whether nonoptimal lipid levels during young adulthood cause atherosclerotic changes that persist into middle age. DESIGN: Prospective cohort study. SETTING (...) : 4 cities in the United States. PARTICIPANTS: 3258 participants from the 5115 black and white men and women recruited at age 18 to 30 years in 1985 to 1986 for the CARDIA (Coronary Artery Risk Development in Young Adults) study. MEASUREMENTS: Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglycerides, and coronary calcium. Time-averaged cumulative exposures to lipids between age 20 and 35 years were estimated by using repeated serum lipid measurements over 20

Full Text available with Trip Pro

2010 Annals of Internal Medicine

184. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. (PubMed)

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. OBJECTIVE: To investigate whether calcium supplements increase the risk of cardiovascular events. DESIGN: Patient level and trial level meta-analyses. DATA SOURCES: Medline, Embase, and Cochrane Central Register of Controlled Trials (1966-March 2010), reference lists of meta-analyses of calcium supplements, and two clinical trial registries. Initial searches were carried out in November 2007 (...) , with electronic database searches repeated in March 2010. STUDY SELECTION: Eligible studies were randomised, placebo controlled trials of calcium supplements (>or=500 mg/day), with 100 or more participants of mean age more than 40 years and study duration more than one year. The lead authors of eligible trials supplied data. Cardiovascular outcomes were obtained from self reports, hospital admissions, and death certificates. RESULTS: 15 trials were eligible for inclusion, five with patient level data (8151

Full Text available with Trip Pro

2010 BMJ

185. Coronary artery calcium score and risk classification for coronary heart disease prediction. (PubMed)

Coronary artery calcium score and risk classification for coronary heart disease prediction. CONTEXT: The coronary artery calcium score (CACS) has been shown to predict future coronary heart disease (CHD) events. However, the extent to which adding CACS to traditional CHD risk factors improves classification of risk is unclear. OBJECTIVE: To determine whether adding CACS to a prediction model based on traditional risk factors improves classification of risk. DESIGN, SETTING, AND PARTICIPANTS

Full Text available with Trip Pro

2010 JAMA

186. Systematic review: vitamin d and calcium supplementation in prevention of cardiovascular events. (PubMed)

Systematic review: vitamin d and calcium supplementation in prevention of cardiovascular events. BACKGROUND: Vitamin D and calcium may affect the cardiovascular system independently and interactively. PURPOSE: To assess whether vitamin D and calcium supplements reduce the risk for cardiovascular events in adults. DATA SOURCES: Studies published in English from 1966 to July 2009 in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. STUDY SELECTION: Two investigators (...) independently selected 17 prospective studies and randomized trials that examined vitamin D supplementation, calcium supplementation, or both and subsequent cardiovascular events. DATA EXTRACTION: Three investigators extracted and checked data about study designs, participants, exposures or interventions, outcomes, and data quality. DATA SYNTHESIS: Five prospective studies of patients receiving dialysis and 1 study involving a general population showed consistent reductions in cardiovascular disease (CVD

2010 Annals of Internal Medicine

188. A prospective randomized controlled trial of a bioresorbable calcium phosphate paste (alpha-BSM) in treatment of displaced intra-articular calcaneal fractures (PubMed)

A prospective randomized controlled trial of a bioresorbable calcium phosphate paste (alpha-BSM) in treatment of displaced intra-articular calcaneal fractures 19820600 2009 10 12 2009 12 02 2016 11 25 1529-8809 67 4 2009 Oct The Journal of trauma J Trauma A prospective randomized controlled trial of a bioresorbable calcium phosphate paste (alpha-BSM) in treatment of displaced intra-articular calcaneal fractures. 875-82 10.1097/TA.0b013e3181ae2d50 Displaced intra-articular calcaneal fractures (...) are devastating injuries and pose a therapeutic challenge. The purpose of this study was to determine whether open reduction internal fixation (ORIF) plus an injectable bioresorbable calcium phosphate paste (alpha-BSM [bone substitute material]) is superior to ORIF alone in the treatment of calcaneal bone voids encountered after operative treatment of displaced intra-articular calcaneal fractures. We prospectively randomized 47 patients with 52 closed displaced intra-articular fractures necessitating

2010 EvidenceUpdates

189. Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets)

Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) Drug Approval Package: Safyral (drospirenone/ethinyl estradiol) NDA #022574 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) Company: Bayer HealthCare Pharmaceuticals Inc. Application No.: 022574 Approval Date: 12/16/2010 Persons

2010 FDA - Drug Approval Package

190. Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium)

Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) Drug Approval Package: Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) NDA #022532 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) tablets Company: Bayer HealthCare Pharmaceuticals Inc. Application No.: 022532 Approval Date: 09/24/2010 Persons

2010 FDA - Drug Approval Package

191. Calcium gluconate injection in small-volume glass containers: new contraindications due to aluminium exposure risk

Calcium gluconate injection in small-volume glass containers: new contraindications due to aluminium exposure risk Calcium gluconate injection in small-volume glass containers: new contraindications due to aluminium exposure risk Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Calcium gluconate injection in small-volume glass containers: new contraindications due to aluminium exposure risk From: Published: 9 August 2010 Therapeutic area: and Aluminium can (...) be leached from glass after contact with calcium gluconate solution, leading to a risk of exposure to aluminium. Accumulation of aluminium might have adverse effects on bone mineralisation and neurological development in children and those with renal impairment. Calcium gluconate injection packed in small-volume glass containers is now contraindicated for use as repeated or prolonged treatment, including as an intravenous infusion, in children younger than 18 years and in patients with renal impairment

2010 MHRA Drug Safety Update

192. Systematic review: Calcium supplements increase risk of myocardial infarction

Systematic review: Calcium supplements increase risk of myocardial infarction Calcium supplements increase risk of myocardial infarction | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Calcium supplements increase risk of myocardial infarction Article Text Therapeutics Systematic review Calcium supplements increase risk of myocardial infarction Sonal Singh 1 , Curt D Furberg 2 Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Bolland MJ , Avenell A , Baron JA , et al . Effect of calcium supplements on risk

2010 Evidence-Based Medicine (Requires free registration)

193. Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension?

Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension? Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension? Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension? Shibata MC, Leon H, Chatterley T, Dorgan M, Vandermeer B CRD summary The review concluded that the results suggested patients with hypertension treated with calcium channel blockers had an increased (...) incidence of heart failure, but that this effect should be researched further. Despite some potential limitations with the review process, and uncertain definitions of heart failure in the included trials (noted by the authors), the authors’ cautious conclusions reflect the evidence presented. Authors' objectives To evaluate whether the use of calcium channel blockers increase the risk of heart failure in patients with hypertension. Searching PubMed (from 1950), EMBASE (from 1988), International

2010 DARE.

194. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events

Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events Wang L, Manson JE, Song Y, Sesso HD CRD summary This review concluded that limited data suggested moderate-to-high doses of vitamin D supplements may reduce cardiovascular disease risk, but calcium supplements (...) may not. Given the potential for missed studies, clinical differences between studies and paucity of good quality data, the reliability of the pooled results is uncertain. However, the authors' conclusions seemed suitably cautious. Authors' objectives To assess whether vitamin D and calcium supplements reduced the risk for cardiovascular events in adults. Searching MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for studies published in English from 1966

2010 DARE.

195. Case control: The use of diuretics plus calcium channel blockers for hypertension may be associated with a higher risk of myocardial infarction but not stroke compared with the combination of diuretics plus ? blockers (PubMed)

Case control: The use of diuretics plus calcium channel blockers for hypertension may be associated with a higher risk of myocardial infarction but not stroke compared with the combination of diuretics plus ? blockers The use of diuretics plus calcium channel blockers for hypertension may be associated with a higher risk of myocardial infarction but not stroke compared with the combination of diuretics plus β blockers | Evidence-Based Medicine This site uses cookies. By continuing to browse (...) the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The use of diuretics plus calcium channel blockers for hypertension may be associated

Full Text available with Trip Pro

2010 Evidence-Based Medicine (Requires free registration)

196. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR CRD summary The review concluded that calcium supplements (without co-administered vitamin D) were associated (...) with an increased risk of myocardial infarction. Overall, the authors' conclusions reflected the evidence presented and appear likely to be reliable. Authors' objectives To investigate whether calcium supplements increase the risk of cardiovascular events. Searching MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched without language restrictions. Search dates ranged from 1966 to March 2010. Search terms were reported. Reference lists of meta-analyses published between

Full Text available with Trip Pro

2010 DARE.

197. Remineralizing White Spot Lesions with Fluoride Alone or Fluoride and Casein Phosphopeptide-Amorphous Calcium Phosphate

Remineralizing White Spot Lesions with Fluoride Alone or Fluoride and Casein Phosphopeptide-Amorphous Calcium Phosphate UTCAT572, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Remineralizing White Spot Lesions With Fluoride Alone Or Fluoride And Casein Phosphopeptide-Amorphous Calcium Phosphate Clinical Question When there are white spot lesions present of enamel, does using fluoride alone or casein phosphopeptide (...) -amorphous calcium phosphate in conjunction with fluoride increase enamel remineralization? Clinical Bottom Line Casein phosphopeptide-amorphous calcium phosphate aids in fluoride uptake by enamel which accounts for more remineralization than just using fluoride alone. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Reynolds/2008 14 healthy participants Randomized comparative

2010 UTHSCSA Dental School CAT Library

198. Efficacy of Casein Phosphopeptide-Amorphous Calcium Phosphate(CPP-ACP)in Remineralizing Demineralized Tooth Structure

Efficacy of Casein Phosphopeptide-Amorphous Calcium Phosphate(CPP-ACP)in Remineralizing Demineralized Tooth Structure UTCAT573, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Efficacy of Casein Phosphopeptide-Amorphous Calcium Phosphate(CPP-ACP)in Remineralizing Demineralized Tooth Structure Clinical Question In a patient with dental caries, is casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) effective (...) an improvement in subsurface remineralization in the group with CPP-ACP. Evidence Search Meta-Analysis, "Dental Caries"[Mesh] "casein phosphopeptide-amorphous calcium phosphate nanocomplex "[Substance Name] Comments on The Evidence A systematic review containing a comprehensive, detailed search for relevant trials (which were each assessed for validity) produced only one study comparing treatment with CPP-ACP to no treatment. This alone is not enough evidence to support the efficacy of CPP-ACP. However

2010 UTHSCSA Dental School CAT Library

199. Evidence supports that toothpaste with arginine, calcium carbonate and fluoride is effective at treating dentin hypersensitivity.

Evidence supports that toothpaste with arginine, calcium carbonate and fluoride is effective at treating dentin hypersensitivity. UTCAT594, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Evidence supports that toothpaste with arginine, calcium carbonate and fluoride is effective at treating dentin hypersensitivity Clinical Question In treating patients with dentin hypersensitivity, is there a better therapeutic (...) treatment for reducing hypersensitivity when compared to fluoride alone? Clinical Bottom Line Toothpaste with arginine, calcium carbonate and fluoride was more effective at immediate relief of dentin hypersensitivity than fluoride alone. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Nathoo/2009 One-hundred and twenty-five subjects from the Piscataway, New Jersey, USA area

2010 UTHSCSA Dental School CAT Library

200. The Effect of a Total Etch Adhesive System versus Calcium Hydroxide in Pulpal Protection of Primary Molars.

The Effect of a Total Etch Adhesive System versus Calcium Hydroxide in Pulpal Protection of Primary Molars. UTCAT598, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title The Effect Of A Total Etch Adhesive System Versus Calcium Hydroxide In Pulpal Protection Of Primary Molars Clinical Question In the pediatric patient with carious lesions in primary molars, does the use of a total etch dental adhesive system (Scotchbond (...) Multipurpose) offer greater pulpal protection subsequent to cavity preparation as compared to a calcium hydroxide liner? Clinical Bottom Line The use of a total etch adhesive system offers comparable protection of the pulp complex as compared to calcium hydroxide liners. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Büyükgüral/2008 97 children ages 5-10 Randomized Controlled

2010 UTHSCSA Dental School CAT Library